United Kingdom signs deals for 90 million COVID-19 vaccine doses

Coronavirus Vaccine

Two coronavirus vaccines show 'promising immune response' in human trials

There are over 100 vaccine candidates in development, though the Trump administration is offering financial support for several leading candidates as part of its "Operation Warp Speed" mission to land shots before the end of the year.

"What this vaccine does particularly well is trigger both arms of the immune system", Dr Hill said.

"We are seeing good immune response in nearly everybody", Dr. Adrian Hill, director of the Jenner Institute at Oxford University, told London AP.

In just six months since the outbreak, 140 vaccine candidates (vaccines under experimentation) are in the pre-clinical trial stage and 23 have entered the clinical evaluation stage, according to the World Health Organization (WHO). AstraZeneca claims that it will not seek to profit from the vaccine, and is already committed to making 200 crore doses.

Dr Wiles said it is likely the company is "hedging its bets" and hoping that the vaccine will be successful.

Researchers said the vaccine caused minor side effects more frequently in the trial than in a control group - but some of these could be reduced by taking paracetamol - with no serious adverse effects from the vaccine.

But experts say it'll take up to 18 months to develop a safe and effective vaccine.

Tesla Cuts Price Of Model Y To Boost Sales Amid Pandemic
Tesla, which recently set a price record, shows a decline of 5.89% on the premarket on Thursday. The five-seat Model Y Long Range has a range of 316 miles and a 0-60 mph time of 4.8 seconds.

Oxford scientists behind the trial have said the preliminary results are "very encouraging", while Boris Johnson has said it is an "important step in the right direction".

The journal also carried the results of clinical trials involving a different vaccine under development in China.

In the study conducted in Germany on 60 healthy volunteers, the vaccine induced virus-neutralising antibodies in those given two doses, in-line with previous results from an early-stage United States trial. The study assessed a single dose of AZD1222 against MenACWY, a comparator meningococcal conjugate vaccine, according to a press release.

But around 70 percent of the participants reported headache and fatigue.

"The difficulty we have, and that all vaccine developers have in trying to make a vaccine against this particular virus, is we don't know how strong that immune response needs to be".

"The fact remains we may never get a vaccine and if we do get one, we have to be prepared that it may not be a vaccine which prevents getting the virus, but rather one that reduces symptoms". The spike protein is what the coronavirus uses to gain entry into cells, so the shot would give our immune system a familiarity with this specific coronavirus without actually having to fight off a full-blown infection.

Latest News